You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging I1 Apr 2016MP73-20 ANALGESIC USE AND RISK OF RENAL CELL CANCER: RESULTS FROM TWO PROSPECTIVE COHORT STUDIES Mark Preston, Xuehong Zhang, Rebecca Graff, Alexander Sanchez, Steven Chang, Meir Stampfer, Toni Choueiri, Kathryn Wilson, and Eunyoung Cho Mark PrestonMark Preston More articles by this author , Xuehong ZhangXuehong Zhang More articles by this author , Rebecca GraffRebecca Graff More articles by this author , Alexander SanchezAlexander Sanchez More articles by this author , Steven ChangSteven Chang More articles by this author , Meir StampferMeir Stampfer More articles by this author , Toni ChoueiriToni Choueiri More articles by this author , Kathryn WilsonKathryn Wilson More articles by this author , and Eunyoung ChoEunyoung Cho More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1675AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Analgesics are the most common over-the-counter drugs worldwide and considerable evidence suggests a beneficial effect of analgesics, especially aspirin, on cardiovascular diseases and colorectal cancer. However, the relationship between the widely used analgesics (i.e., aspirin, other nonsteroidal anti-inflammatory drugs (NSAID), and acetaminophen) and risk of total and lethal renal cell cancer remains unclear. METHODS We examined the associations between analgesic use and risk of renal cell cancer overall and by subtypes, in the Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS). We collected information on aspirin, other non-aspirin NSAIDs, and acetaminophen in 1990 in the NHS and in 1986 in the HPFS, and every 2 years thereafter. We used Cox proportional hazards models, controlling for other known and suspected risk factors, to examine the associations between baseline and duration of use of each analgesic and risk of total renal cell cancer, lethal renal cell cancer (resulted in death due to disease), as well as clear cell renal cell cancer. We pooled results using a random-effects model. RESULTS During follow-up of 22 years among 77,527 women and 26 years among 45,913 men, we documented 438 cases of renal cell cancer (230 in women and 208 in men), of which 106 were fatal (56 in women and 40 in men) and 300 were clear cell (165 in women and 135 in men). The pooled multivariable relative risks (RRs) for total renal cell cancer were 1.13 (95% CI: 0.91-1.39) for aspirin use, 1.34 (95% CI: 1.03-1.75) for non-aspirin NSAID use, and 1.07 (95% CI: 0.80-1.44) for acetaminophen use. Similar results were observed for lethal renal cell cancer and clear cell renal cell cancer. Importantly, longer duration of non-aspirin NSAID use was associated with an increased risk of renal cell cancer. The pooled (all p-heterogeneity > 0.05) multivariable RRs for total renal cell cancer were 1.23 (95% CI: 0.94-1.62) for non-aspirin NSAID users of 4-10 years and 1.81 (95% CI: 1.21-2.72) for over 10 years. The corresponding RRs were 1.91 (95% CI: 1.04-3.49) and 3.97 (95% CI: 1.46-10.83) for lethal renal cell cancer, and 1.36 (95% CI: 0.99-1.88) and 1.58 (95% CI: 0.94-2.63) for clear cell renal cell cancer. CONCLUSIONS Our findings support a significant positive association between non-aspirin NSAID use and risk of developing renal cell cancer, especially the lethal form. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e968 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Mark Preston More articles by this author Xuehong Zhang More articles by this author Rebecca Graff More articles by this author Alexander Sanchez More articles by this author Steven Chang More articles by this author Meir Stampfer More articles by this author Toni Choueiri More articles by this author Kathryn Wilson More articles by this author Eunyoung Cho More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...